Literature DB >> 15386357

Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from calophyllum brasiliense that acts by induction of apoptosis.

Shinya Kimura1, Chihiro Ito, Naoto Jyoko, Hidekazu Segawa, Junya Kuroda, Masayuki Okada, Souichi Adachi, Tatsutoshi Nakahata, Takeshi Yuasa, Valdir Cechinel Filho, Hiroshi Furukawa, Taira Maekawa.   

Abstract

During our search for cancer chemopreventing compounds derived from plant sources, we discovered that the natural product GUT-70, isolated from the stem bark of Calophyllum brasiliense collected in Brazil, significantly inhibits the growth of leukemic cells. GUT-70, characterized as a tricyclic coumarin, 5-methoxy-2,2-dimethyl-6-(2-methyl-1-oxo-2-butenyl) -10-propyl-2H,8H-benzo[1,2-b;3,4-b']dipyran-8-one (C(23)H(26)O(5)), inhibited all 6 human leukemic cell lines evaluated, including the P-glycoprotein overexpressing cell line, in a concentration and time-dependent manner with IC(50) values from 2-5 microM. Furthermore, GUT-70 did not inhibit colony formation by normal hematopoietic progenitors up to 30 microM and also did not inhibit the proliferation of normal human hepatocytes up to 30 microM. GUT-70 activated the caspase 2, 3, 8 and 9, and induced the apoptosis in leukemic cells, which was inhibited by caspase inhibitors. GUT-70 induced anti-leukemic effects independent of the p53-p2l(WAFl/CIP1) pathway and increased the overall expression of p27(KIP1) and p57(KIP2), to stop the cell cycle at the G(1)/S transition. Thus, a novel anti-cancer drug, GUT-70 isolated from the stem bark of C. brasiliense induces caspase-mediated and p53-independent apoptosis to overcome multidrug resistance and may become a potent leukemia therapeutics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15386357     DOI: 10.1002/ijc.20505

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  The validation of Calophyllum brasiliense ("guanandi") uses in Brazilian traditional medicine as analgesic by in vivo antinociceptive evaluation and its chemical analysis.

Authors:  Luiz Carlos Klein-Júnior; Daniele Zambiasi; Giovana Rocha Salgado; Franco Delle Monache; Valdir Cechinel Filho; Fátima de Campos Buzzi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-08       Impact factor: 3.000

Review 2.  Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

Authors:  Qian Zhang; Yunjiang Feng; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

3.  Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.

Authors:  L Jin; Y Tabe; S Kimura; Y Zhou; J Kuroda; H Asou; T Inaba; M Konopleva; M Andreeff; T Miida
Journal:  Br J Cancer       Date:  2010-12-07       Impact factor: 7.640

Review 4.  P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review.

Authors:  Hossam M Abdallah; Ahmed M Al-Abd; Riham Salah El-Dine; Ali M El-Halawany
Journal:  J Adv Res       Date:  2014-12-01       Impact factor: 10.479

5.  Calophyllum brasiliense Modulates the Immune Response and Promotes Leishmania amazonensis Intracellular Death.

Authors:  L Domeneghetti; I G Demarchi; J Z Caitano; R B Pedroso; T G V Silveira; M V C Lonardoni
Journal:  Mediators Inflamm       Date:  2018-02-13       Impact factor: 4.711

Review 6.  Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition.

Authors:  Saikat Dewanjee; Tarun K Dua; Niloy Bhattacharjee; Anup Das; Moumita Gangopadhyay; Ritu Khanra; Swarnalata Joardar; Muhammad Riaz; Vincenzo De Feo; Muhammad Zia-Ul-Haq
Journal:  Molecules       Date:  2017-05-25       Impact factor: 4.411

Review 7.  Chemical constituents of the plants of the genus Calophyllum.

Authors:  Xiao-Hui Su; Man-Li Zhang; Li-Geng Li; Chang-Hong Huo; Yu-Cheng Gu; Qing-Wen Shi
Journal:  Chem Biodivers       Date:  2008-12       Impact factor: 2.408

Review 8.  Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.

Authors:  Hager Mohamed; Theodore Gurrola; Rachel Berman; Mackenzie Collins; Ilker K Sariyer; Michael R Nonnemacher; Brian Wigdahl
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.